Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With Leptomeningeal Metastases

NCT06926803 is registered in ClinicalTrials.gov with Qiming Wang as lead sponsor.

NCT NCT06926803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06926803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With Leptomeningeal Metastases
Lead sponsor
Qiming Wang
Phase
Observational
Overall status
Active, not recruiting
Start date
March 1, 2025
Completion date
August 1, 2025
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leptomeningeal cancer, lung cancer (nsclc)